Preface

Catalyzed by the COVID-19 pandemic, technological innovation has flourished across the healthcare sector, ushering in a golden age for life sciences and accelerating the restructuring of the global R&D, manufacturing, and sales landscape within the medical and health industry. Notably, AI-driven drug discovery, along with cell and gene therapy technologies, is powerfully facilitating breakthroughs in biopharmaceuticals and clinical treatment, breaking through previous constraints and unleashing robust innovative vitality.

The future is already here. We aim to use industrial research as a cornerstone to identify pioneering innovators in the biopharmaceutical industry, focusing on innovative development, technological transformation, and policy evolution within the biopharmaceutical sector, while also examiningAI+Drug R&D, Cell and Gene TherapyStarting from two value domains, identify innovative enterprises with high growth potential and select the “2021 Biopharma Value Sector Rankings”。

Click the image to participate in the ranking submission.

Identifying candidate drugs and their therapeutic targets is the primary objective of drug discovery. Artificial intelligence is empowering new drug development across disciplines, driving exponential improvements in screening efficiency. Robust supply chains and R&D capabilities have fostered the emergence of numerous outstanding pharmaceutical companies and digital service providers, enabling hundreds of millions of patients to benefit from technology-driven drug iterations. Data indicate that the AI-enabled new drug discovery market will maintain an annual growth rate of 31.6% from 2020 to 2027, with its market value projected to exceed $30 billion within six years.

Eligible Candidates:A service provider that leverages technologies such as cloud computing, big data, the Internet of Things (IoT), the internet, and artificial intelligence to deliver digital drug R&D platform services and solutions for the early-stage research and development of biopharmaceutical companies.

Eligibility Criteria:A. Non-listed companies in the field; B. Operational as of the selection date and capable of sustained operations; C. Have secured at least angel-round financing; D. Maintain physical entities and business operations in China; E. No major corporate violations within the past three years; F. Established within the last 10 years.

According to McKinsey data, as of February 2020, 16 of the top 20 global pharmaceutical companies had established cell and gene therapy (CGT) R&D pipelines, marking the transition of CGT from a hyped concept to the stage of commercial realization. With sustained capital infusion, the market value is projected to exceed RMB 100 billion within the next five years. Deepening industrial synergy offers greater promise for achieving “full-lifecycle” cures for patients with cancer, rare diseases, and various genetic disorders. The future undoubtedly belongs to the era of cell and gene therapy.

Eligible Candidates:Developer and service provider of cell and gene therapy technologies; R&D and manufacturer of cell and gene therapy drugs.

Eligibility Requirements:A. Non-listed companies in the field; B. Operational as of the selection date and capable of sustained operations; C. Have secured at least angel-round financing; D. Maintain physical entities and business operations in China; E. No major corporate violations within the past three years; F. Established within the last 10 years.

Effective Immediately–September 30: List Registration

October 8–10: Ranking Evaluation and Review

October 14: Release of the On-Site Rankings at the 2021 MTF Future Medical Technology Trends Forum (Shenzhen, Nanshan)

Submission Link:http://vcbeat-vb100.mikecrm.com/joqz0L4

The form contains extensive text; we recommend completing it on a PC. A VCBeat representative will contact you within two business days.

Scan the QR code to register!

·Community-Wide Resource Recommendations:

Online article dissemination to increase exposure for listed companies, with recommendations across the entire VCBeat community, and provision of industry/capital matchmaking services following coverage.

·InvitedAttendance2021MTF · Future Healthcare Technology Trends Forum：

Invited to attend the forum and participate in the awards ceremony. Centered on “Medical Technology,” the forum focused on hot topics such as new global trends in drug innovation and the digitalization and intelligence of pharmaceutical R&D, exploring the latest industry development trends in biomedicine and the future of frontier technologies.

Conference Time: October 14, 2021 (Thursday) 9:00-17:00

Venue: Talent Research Institute, Nanshan District, Shenzhen

Registration Link:http://hdxu.cn/pgfQW

· Peak Dialogue, In-Depth DiscussionRegional Industry Development:

Invited to participate in the industry symposium held concurrently with the forum, engaging in discussions and interactions with policy and industry experts from Shenzhen on topics such as the support needed for enterprise development and the strategic planning of the biopharmaceutical industry.

· Direct Entry for the 2022 Future Healthcare Top 100 Conference/Shortlist Application:

The organizing committee will provide participating companies with five tickets to the 2022 Top 100 Future Healthcare Companies Conference. Companies already on the list that wish to participate in the 2022 selection again will be exempt from submitting basic application materials; they need only supplement and refine their previous submissions.